Research and Markets: Endometriosis – Pipeline Review, H2 2015

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Endometriosis
– Pipeline Review, H2 2015”
report to their offering.

This report provides comprehensive information on the therapeutic
development for Endometriosis, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Endometriosis and special features on late-stage and discontinued

The report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report enhances
decision making capabilities and help to create effective counter
strategies to gain competitive advantage. It strengthens R&D pipelines
by identifying new targets and MOAs to produce first-in-class and
best-in-class products.

Reasons to buy:

  • Provides strategically significant competitor information, analysis,
    and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of
    leading companies
  • Identify and understand important and diverse types of therapeutics
    under development for Endometriosis
  • Plan mergers and acquisitions effectively by identifying key players
    of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding
    Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects
    and understanding the factors that drove them from pipeline

Companies Mentioned:

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • APAvadis Biotechnologies Srl
  • Astellas Pharma Inc.
  • Bayer AG
  • Dongkook Pharmaceutical Co., Ltd.
  • ElexoPharm GmbH
  • EndoCeutics, Inc.
  • Enteris BioPharma, Inc.
  • Euroscreen S.A.
  • Evotec AG
  • Forendo Pharma Oy
  • GlaxoSmithKline Plc
  • Kissei Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • Nippon Shinyaku Co., Ltd.
  • Orphagen Pharmaceuticals, Inc.
  • Philogen S.p.A.
  • Repros Therapeutics Inc.
  • SK Chemicals Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • ValiRx Plc

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune